SUNRISE, Fla., May 3 (UPI) -- Bioheart said Wednesday it had gained rights to Tricardia's patents for a needle that will be attached to Bioheart's MyoCath system.
Under the terms of the agreement, Bioheart gets worldwide exclusive rights to four U.S. patents and corresponding foreign filings that cover the needle and its use in delivering therapies to the heart.
The needle, which has a closed tip and side holes that provide for multidirectional injection into a beating heart, will be incorporated into Bioheart's SR-200 MyoCath needle injection catheter system.
"The modified needle covered by these licensed patents will provide us with another tool to improve the retention of Bioheart's therapeutic cell composition within a patient's heart," said Howard Leonhardt, Bioheart's chairman and chief executive officer.
"We are hopeful that this development will lead to even better outcomes for the many heart failure patients we are attempting to treat," Leonhardt added.
